Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CMA1 | P23946 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103262 | 0.86 | SMN1; SMN2 (0.34) | TDP1SMN1; SMN2ENPP1MAPTALDH1A1 | |
| SCHEMBL7101214 | 0.84 | GPR35 (0.32) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7100988 | 0.83 | CYP1A2 (0.32) | MAPTALDH1A1 | |
| SCHEMBL7172007 | 0.81 | KDM4E (0.32) | SMN1; SMN2TSHRKDM4E | |
| SCHEMBL7101641 | 0.78 | MEN1 (0.39) | TDP1SMN1; SMN2TSHRMAPTALDH1A1 | |
| SCHEMBL7103392 | 0.77 | NOS3 (0.34) | SMN1; SMN2MAPTALDH1A1PKM | |
| SCHEMBL7103291 | 0.76 | TDP1 (0.38) | TDP1SMN1; SMN2TSHRMAPTALDH1A1 | |
| SCHEMBL7102328 | 0.76 | CYP19A1 (0.37) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7510881 | 0.72 | FGFR1 (0.35) | SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL22075719 | 0.72 | MEN1 (0.41) | SMN1; SMN2TSHRMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | TDP1 2857/4885SMN1; SMN2 639/4885TSHR 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.